---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241415"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:35:10.587048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires

## Summary
- Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.
- TSHA-102 has FDA Breakthrough Therapy designation; Part A REVEAL data showed 100% response rate on primary endpoint.
- REVEAL pivotal trial dosing of first patient scheduled this quarter; FDA alignment on protocol and SAP obtained.
- Unencumbered rights enable full strategic flexibility and optionality for Taysha.

## SEC filing metadata
- accession: 0001193125-25-241415
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/0001193125-25-241415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/d35488d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241415
- JSON: https://secwatch.observer/filing/0001193125-25-241415.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.